What You Should Know:
– Neurocode USA, Inc., a provider of neurological testing, has announced the launch of ALZpath Dx, a novel blood test for Alzheimer’s disease (AD) in the United States.
– The availability of ALZpath Dx marks a significant advancement in AD diagnosis and management. This non-invasive and highly accurate blood test offers a powerful tool for earlier detection, improved patient care, and the development of new treatment options.
A New Era in AD Diagnostics:
ALZpath Dx measures pTau217, a protein biomarker closely linked to AD pathology. This minimally invasive blood test offers numerous advantages over traditional diagnostic methods:
– Non-invasive: Eliminating the need for more invasive procedures like spinal taps.
– Earlier detection: Enabling earlier diagnosis and intervention, potentially leading to better patient outcomes.
– Improved accuracy: Demonstrating high diagnostic accuracy, exceeding that of other blood-based tests.
– Enhanced clinical trials: Facilitating better patient selection for clinical trials of new AD treatments.
– Personalized treatment plans: Providing valuable insights for developing individualized treatment plans.
Validation Study/Results
Neurocode is the first laboratory globally to offer ALZpath Dx for clinical use within a CAP-accredited and CLIA-certified facility. Their rigorous validation study, involving over 1,700 samples and 150 autopsies, demonstrated exceptional accuracy. This study yielded an area under the curve (AUC) of 0.94, significantly exceeding the 90% accuracy threshold proposed by the Alzheimer’s Association for standalone AD diagnostic tests.
